Multicenter Observational Study on Infant Botulism in Pediatric Intensive Care
PDF (Español (España))
HTML (Español (España))

Keywords

Infant botulism
Intensive care
mouse bioassay

Categories

How to Cite

1.
Kaltenbach GH, Ávila C, Cárdenas M, Arias V, Llarenas P, Palacio K, et al. Multicenter Observational Study on Infant Botulism in Pediatric Intensive Care. Rev Arg de Ter Int. [Internet]. 2022 Dec. 26 [cited 2024 Jul. 3];39. Available from: https://revista.sati.org.ar/index.php/MI/article/view/844

Abstract

Introduction. Infant botulism presents with potentially severe flaccid paralysis. Argentina has an incidence of 2.41 cases/100,000 live births.

Objective. To describe the clinical characteristics of patients with Infant botulism hospitalized in Pediatric Intensive Care Units.

Material and Methods. Retrospective, observational, multicentric study conducted between 01-01-2013 and 31/12/2019.  

Results. A total of sixty patients were included, all diagnosed with the mouse bioassay. Conventional mechanical ventilation was administered to 80%, Non-Invasive Ventilation to 27%; 30% received antitoxin. The median Intensive Care stay was 25 days (IRD: +-18.5) and median conventional mechanical ventilation was  27 days (IRD +-14.5). Delay in diagnostic confirmation: median 16 days (IQR 13-18.5).

Conclusions. Infant botulism presented prolonged periods of hospitalization and mechanical ventilation; only 30% of patients received antitoxin. The diagnostic confirmation delay time exceeded the recommended antitoxin administration window.

PDF (Español (España))
HTML (Español (España))

References

Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976-2006. Pediatrics 2008; 122(1): e73-82. https://doi.org/10.1542/peds.2007-1827

Lúquez C, Bianco M, Sagua M, et al. Relationship between the incidence of infant botulism and the presence of botulinum-toxin producing Clostridia in the soil of Argentina from 1982–2005. J Pediatr Neurol 2007; 5: 279-286. https://doi.org/10.1055/S-0035-1557408

Johnson EA, Tepp WH, Bradshaw M, Gilbert RJ, Cook PE, McIntosh DG. Characterization of Clostridium botulinum strains associated with an infant botulism case in the United Kingdom. J Clin Microbiol 2005; 43(6): 2602-2607. https://doi.org/10.1128/JCM.43.6.2602-2607.2005

Drivenes B, Krause T, Andersson M, Müller L, et al. Infant botulism in Denmark from 1995 to 2015. Dan Med J 2017; 64(9): A5404. PMID: 28874241

Ministerio de Salud de la Nación. Guía de Prevención, Diagnóstico, Tratamiento y Vigilancia Epidemiológica del Botulismo del Lactante. Buenos Aires, 2012. (Consulta: 21 de marzo 2021). Disponible en: https://www.toxicologia.org.ar

Centers for Disease Control. Infant Botulism: information for clinicians. (Consulta: 1 de junio 2021). Disponible en: https://www.cdc.gov/botulism/infant-botulism.html

Hobbs R, Thomas C, Halliwell J, et al. Rapid detection of botulinum neurotoxins-A review. Toxins (Basel) 2019; 11(7): 418. https://doi.org/10.3390/toxins11070418

Jackson KA, Mahon BE, Copeland J, Fagan RP. Botulism mortality in the USA, 1975-2009. Botulinum J 2015; 3(1): 6-17. https://doi.org/10.1504/TBJ.2015.078132

Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006; 2: 354(5): 462-471. https://doi.org/10.1056/NEJMoa051926

Chalk CH, Benstead TJ, Pound JD, Keezer M. Medical treatment for botulism. Cochrane Database Syst Rev 2019; 4(4): CD008123. https://doi.org/10.1002/14651858.CD008123.pub4

Moneim J. Question 1: In infant botulism, is equine-derived botulinum antitoxin (EqBA) an effective alternative therapy to human-derived botulinum immune globulin (BIG)? Arch Dis Child 2018; 103(9): 907-909. https://doi.org/10.1136/archdischild-2018-315498

Ministerio de Salud de la Nación. Boletín Integrado de Vigilancia Epidemiológica. (Consulta: 21 de julio 2021). Disponible en: https://bancos.salud.gob.ar/bancos/materiales-para-equipos-de-salud/soporte/boletines-epidemiologicos/

Dilena R, Pozzato M, Baselli L, et al. Infant botulism: checklist for timely clinical diagnosis and new possible risk factors originated from a case report and literature review. Toxins 2021; 13(12): 860. https://doi.org/10.3390/toxins13120860

Vanella de Cuetos EE, Fernández RA, Bianco MI, et al. Equine botulinum antitoxin for the treatment of infant botulism. Clin Vaccine Immunol 2011; 18(11): 1845-1849. https://doi.org/10.1128/CVI.05261-11

Khouri, JM, Payne JR, Arnon SS. More clinical mimics of infant botulism. J Pediatr 2018; 193: 178-182. https://doi.org/10.1016/j.jpeds.2017.09.044

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Copyright (c) 2022 German Hugo Kaltenbach, Carla Ávila, María Cárdenas, Viviana Arias, Pablo Llarenas, Karina Palacio, Marcelo Moyano, Juan Martinez, Patricia Rust